TIME Operations Manager

Pathos AI teams up with Bristol Myers and Tempus AI to advance drug development. By Thomson Reuters Oct 23, 2026 | 9:00 AM Oct 23 (Reuters) - Pathos AI said on Friday it had entered into a collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological disorders. Pathos AI also raised $237 million in a Series E funding round led by Bristol Myers that valued the New York-based company at about $3 billion, with participation from existing investors. Here are some other details: - Tempus will build a dataset from hundreds of thousands of patients with neurological disorders to help track outcomes and speed research into disease biology - Pathos will license the data from Tempus under a five-year, $55 million agreement - Pathos will apply its AI platform, Pathos Foundry, to study the dataset at scale, generate and test hypotheses on disease biology, and inform the design of more targeted, adaptive clinical trials - Bristol Myers will gain non-exclusive strategic access to Pathos Foundry across its broader portfolio, as well as three-year exclusive rights to use the platform for its neuroscience development programs - Proceeds from the financing will be used to further scale the Foundry platform's capabilities and accelerate development of its AI-driven pipeline, including advancing experimental cancer drug, JSKN016 - The funding will help advance development of other cancer programs including an AstraZeneca-partnered experimental breast cancer drug (Reporting by Sriparna Roy in Bengaluru; Editing by Maju Samuel)

Tempus announces multi-year collaboration with Moderna and Merck. Key Takeaway: Tempus has announced a multi-year collaboration with Moderna and Merck to support the commercialization of intismeran autogene, a novel individualized neoantigen therapy. This therapy is being evaluated in combination with Merck's KEYTRUDA for patients with completely resected stage IIB-IV melanoma and other cancers. The collaboration signifies a significant step in cancer treatment innovation. Market sentiment analysis. Positive factors. * Collaboration aims to support commercialization of innovative therapy. * Intismeran autogene is a potential first-in-class treatment. * Combination therapy with KEYTRUDA may enhance cancer treatment options. BiopharmaWatch analysis. From its catalyst data and publicly available data · not financial advice Best trade, last catalyst 120-day peak, hindsight Typical move average across 9 past catalysts Cash runway Minimal dilution risk Lead asset Phase 2 · Influenza CHICAGO-(BUSINESS WIRE)-Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization of intismeran autogene (V940/mRNA-4157), a novel, potential first-in-class individualized neoantigen therapy (INT) being evaluated in combination with KEYTRUDA(R)(pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, know Frequently asked questions. What is the focus of the Tempus collaboration? The collaboration focuses on supporting the commercialization of intismeran autogene. Which therapy is intismeran autogene combined with? Intismeran autogene is evaluated in combination with KEYTRUDA. What types of cancer are targeted in this collaboration? The collaboration targets completely resected stage IIB-IV melanoma and other cancers. Who are the partners in the collaboration? The partners are Tempus, Moderna, and Merck.

Leica Biosystems adds Paige products to Aperio AI Store. * September 25, 2026 Leica Biosystems has added two Paige digital pathology AI-enabled products from Tempus to its growing Aperio AI Store - a unified, interoperable digital pathology platform that provides multiple AI-powered applications in a single interface. Designed to simplify adoption and accelerate the use of advanced image analysis, the Aperio AI Store helps turn complex pathology images into actionable research insights that could ultimately drive the future of patient care. By bringing leading partner applications into a streamlined workflow, the Aperio AI Store helps laboratories and researchers generate insights from pathology images more efficiently and at scale, supporting broader adoption of computational pathology and helping unlock the full value of digital pathology data for cancer research. The newly available products include Paige PanCancer Detect, a groundbreaking research application designed to identify suspicious areas across more than 40 cancer types, powered by Tempus' pathology foundation model. The release also features Paige Prostate, a suite of AI-powered research applications - including Paige Prostate Detect, Paige Prostate Grade & Quantify, and Paige Perineural Invasion - that support the assessment of prostate cancer features in H&E-stained whole-slide images. Both products are for research use only and are not intended for diagnostic or clinical use. As digital pathology adoption grows, pathologists need AI tools that integrate naturally into existing workflows. The Aperio AI Store is designed to simplify and scale AI adoption by bringing partner algorithms directly into the Aperio HALO AP software workflow. Instead of navigating separate software interfaces for each algorithm or vendor, users can access a broad and growing selection of curated AI applications through one consistent experience. For laboratories evaluating multiple AI tools across diverse case types, this approach can help reduce complexity and support more efficient adoption. "Nearly one year after launch, the Aperio AI Store is helping move AI in digital pathology from individual applications toward a more connected and scalable experience," said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems. "Tempus brings highly differentiated AI capabilities to our ecosystem, giving laboratories more choice while allowing them to access these technologies within a workflow they already know. This is an important step toward making AI more practical, scalable, and ultimately more impactful in pathology." Available exclusively through the Aperio HALO AP image management system, the Aperio AI Store has gained momentum since its U.S. launch in October 2025 by offering a practical suite of AI tools within a pathologist-centric, interoperable digital pathology workspace. Aperio HALO AP is developed in partnership with Indica Labs. In the USA Aperio HALO AP is For Research Use Only. Not for use in diagnostic procedures. Aperio HALO AP is CE-IVDR marked in the EU. All other products are For Research Use Only. Not for use in diagnostic procedures.